Peter Kies - 20 May 2026 Form 4 Insider Report for INOVIO PHARMACEUTICALS, INC. (INO)

Reporting relationship: CFO
Issuer ticker: INO
Reported as of: 20 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 May 2026, 16:04:32 UTC
Prior SEC filing: 18 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Peter Kies

Key filing fact

Peter Kies filed Form 4 for INOVIO PHARMACEUTICALS, INC. (INO) on 21 May 2026.

Key facts

This page summarizes Peter Kies's Form 4 filing for INOVIO PHARMACEUTICALS, INC. (INO).
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 21 May 2026, 16:04.

Change

Previous filing in this sequence was filed on 18 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001259780 Primary reporting owner

KIES PETER

Relationship: CFO
Address: C/O INOVIO PHARMACEUTICALS, INC., 6769 MESA RIDGE ROAD, SAN DIEGO
Signature: /s/ Peter Kies
Signature date: 21 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INO transaction

Common Stock

Options Exercise

Transaction value
Shares: +8,700
Change %: +22%
Price
Shares after: 47,542
Date: 20 May 2026
Ownership: Direct
Footnotes: F1

INO transaction

Common Stock

Tax liability

Transaction value
Shares: -4,688
Change %: -9.9%
Price: $1.23^*
Shares after: 42,854
Date: 20 May 2026
Ownership: Direct
Footnotes: F2

INO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 375
Date: 20 May 2026
Ownership: By Spouse

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INO transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
Shares: -8,700
Change %: -33%
Price: $0.000000^*
Shares after: 17,400
Date: 20 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,700
Exercise price
Footnotes: F1

INO transaction Derivative

Common Stock Option

Award

Transaction value
Shares: +39,760
Change %
Price: $0.000000^*
Shares after: 39,760
Date: 20 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 39,760
Exercise price: $1.73
Footnotes: F3, F4

INO transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +32,480
Change %
Price: $0.000000^*
Shares after: 32,480
Date: 20 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 32,480
Exercise price
Footnotes: F5, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 26,100 restricted stock units was as follows: 8,700 shares vested on May 20, 2026; 8,700 shares will vest on May 20, 2027; 8,700 shares will vest on May 20, 2028. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Footnote F2

The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.

Footnote F3

The stock option grant was approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the stock options were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026.

Footnote F4

The vesting schedule for the options granted on May 20, 2026 was as follows: 13,254 shares will vest on February 26, 2027; 13,253 shares will vest on February 26, 2028; 13,253 shares will vest on February 26, 2029.

Footnote F5

Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the restricted stock units granted on May 20, 2026 was as follows: 10,827 shares will vest on February 26, 2027; 10,827 shares will vest on February 26, 2028; and 10,826 shares will vest on February 26, 2029. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Footnote F6

The restricted stock units were approved by Inovio's Board of Directors on March 4, 2026, subject to shareholder approval of the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan under which the restricted stock units were granted. Inovio's shareholders approved the amendment and restatement of the Amended and Restated 2023 Omnibus Incentive Plan on May 20, 2026.